<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313490433</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313490433</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Gómez-Puerta</surname><given-names>JA</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313490433">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313490433"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Cervera</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313490433">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203313490433"><label>1</label>Division of Rheumatology, Immunology and Allergy, Section of Clinical Sciences, Brigham and Women's Hospital, Boston, MA, USA</aff>
<aff id="aff2-0961203313490433"><label>2</label>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain</aff>
<author-notes>
<corresp id="corresp1-0961203313490433">Correspondence to: Jose A Gómez-Puerta, Division of Rheumatology, Immunology and Allergy, Section of Clinical Sciences, Brigham and Women's Hospital, 221 Longwood Ave., Boston, MA 02115 USA. Email: <email>jgomezpuerta@partners.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>7</issue>
<fpage>754</fpage>
<lpage>755</lpage>
<history>
<date date-type="received"><day>8</day><month>2</month><year>2013</year></date>
<date date-type="accepted"><day>20</day><month>4</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Sir,</p>
<p>Recently, Alijotas-Reig<sup><xref ref-type="bibr" rid="bibr1-0961203313490433">1</xref></sup> reported a comprehensive review focused on the management of refractory cases of antiphospholipid syndrome (APS) presenting during the obstetric period. The author addressed some potential alternatives for the treatment of refractory obstetric APS, including double anti-aggregant therapy, intravenous immunoglobulins, and biologic therapies, especially anti-tumor necrosis factor (TNF)-α agents.<sup><xref ref-type="bibr" rid="bibr1-0961203313490433">1</xref></sup></p>
<p>We would like to comment on two additional treatment options. Alijotas-Reig especially emphasized the potential utility of anti-TNF-α agents, including infliximab (INF), etanercept (ETC), and adalimumab (ADA); however, no mention of certolizumab (CZP) was made. Additionally, the author does not comment on the potential role of plasma exchange (PE) therapy during pregnancy, including catastrophic APS (CAPS) events.<sup><xref ref-type="bibr" rid="bibr2-0961203313490433">2</xref>,<xref ref-type="bibr" rid="bibr3-0961203313490433">3</xref></sup></p>
<p>CZP is a PEGylated Fab’ fragment of humanized anti-TNF-α monoclonal antibody, rather than a whole human immunoglobulin G1 (IgG1) antibody, such as INF or ADA.<sup>4</sup> Whole IgG antibodies cross the placenta via specific neonatal receptors (FcRns).<sup><xref ref-type="bibr" rid="bibr5-0961203313490433">5</xref></sup></p>
<p>Most information about the use of anti-TNF-α therapies during pregnancy comes from inflammatory bowel disease studies<sup><xref ref-type="bibr" rid="bibr5-0961203313490433">5</xref>,<xref ref-type="bibr" rid="bibr6-0961203313490433">6</xref></sup> and from national registries.<sup><xref ref-type="bibr" rid="bibr7-0961203313490433">7</xref></sup> Although anti-TNF-α drugs do not seem to increase the risk of complications during pregnancy and seem to be safe for the newborn, an increased rate of spontaneous abortions was observed in women exposed to anti-TNF-α therapies at conception.<sup><xref ref-type="bibr" rid="bibr7-0961203313490433">7</xref></sup></p>
<p>Despite the fact that anti-TNF-α could be relatively safe for the baby, those therapies are not free of adverse events for the mother. Those adverse effects include infusion or injection site reactions, increased risk of serious infections, including bacterial infections, tuberculosis, and opportunistic infections, among others. So, clinicians must be aware of those events and balance the benefits and risks of using them during pregnancy.</p>
<p>If the decision to continue INF or ADA throughout pregnancy is made, it should be avoided during the third trimester when transplacental transfer is at its greatest.</p>
<p>The placental transfer is not the same for all anti-TNF-α therapies. Recently, Mahadevan et al.<sup><xref ref-type="bibr" rid="bibr5-0961203313490433">5</xref></sup> reported a study that included 31 pregnant women with Crohn’s disease who were exposed to three different anti-TNF therapies. Eleven pregnant patients were exposed to INF, 10 patients to CZP, and 10 patients to ADA. When comparing placental transfer measured by cord blood levels at birth, CZP had minimal placental transfer. Conversely, INF and ADA levels were considerably higher. IFX and ADA could be detected in the infants for as long as six months, thus raising some concerns regarding the risk of infection and response to vaccines during the neonatal period.</p>
<p>Finally, we would like to stress the utility of PE sessions in pregnant patients with APS and, especially, with CAPS. The basic principle of PE is the removal of large molecular-weight substances, including autoantibodies and immune complexes.<sup><xref ref-type="bibr" rid="bibr8-0961203313490433">8</xref></sup></p>
<p>PE has been used in pregnant patients with primary APS with previous thrombotic events<sup><xref ref-type="bibr" rid="bibr2-0961203313490433">2</xref></sup> and is crucial in CAPS.<sup><xref ref-type="bibr" rid="bibr9-0961203313490433">9</xref></sup> El-Haeig et al.<sup><xref ref-type="bibr" rid="bibr10-0961203313490433">10</xref></sup> evaluated the efficacy of PE plus low doses of prednisone in 18 pregnant APS patients, most of them with previous history of fetal losses and/or severe preeclampsia. The authors achieved very satisfactory results, with a live birth rate of 100%, no neonatal deaths, and no cases of severe preeclampsia.</p>
<p>Therefore, CZP and PE sessions must be included in the therapeutic arsenal for refractory obstetric APS.</p>
</body>
<back>
<sec id="sec1-0961203313490433"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec2-0961203313490433"><title>Conflict of interest</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313490433"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alijotas-Reig</surname><given-names>J</given-names></name></person-group>. <article-title>Treatment of refractory obstetric antiphospholipid syndrome: The state of the art and new trends in the therapeutic management</article-title>. <source>Lupus</source> <year>2013</year>; <volume>22</volume>: <fpage>6</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr2-0961203313490433"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bontadi</surname><given-names>A</given-names></name><name><surname>Ruffatti</surname><given-names>A</given-names></name><name><surname>Marson</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome</article-title>. <source>J Clin Apher</source> <year>2012</year>; <volume>27</volume>: <fpage>200</fpage>–<lpage>204</lpage>.</citation></ref>
<ref id="bibr3-0961203313490433"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gómez-Puerta</surname><given-names>JA</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Espinosa</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Catastrophic antiphospholipid syndrome during pregnancy and puerperium: Maternal and fetal characteristics of 15 cases</article-title>. <source>Ann Rheum Dis</source> <year>2007</year>; <volume>66</volume>: <fpage>740</fpage>–<lpage>746</lpage>.</citation></ref>
<ref id="bibr4-0961203313490433"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>ED</given-names></name></person-group>. <article-title>Certolizumab pegol: A review of its use in the management of rheumatoid arthritis</article-title>. <source>Drugs</source> <year>2013</year>; <volume>73</volume>: <fpage>75</fpage>–<lpage>97</lpage>.</citation></ref>
<ref id="bibr5-0961203313490433"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahadevan</surname><given-names>U</given-names></name><name><surname>Wolf</surname><given-names>DC</given-names></name><name><surname>Dubinsky</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease</article-title>. <source>Clin Gastroenterol Hepatol</source> <year>2013</year>; <volume>11</volume>: <fpage>286</fpage>–<lpage>292</lpage>.</citation></ref>
<ref id="bibr6-0961203313490433"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schnitzler</surname><given-names>F</given-names></name><name><surname>Fidder</surname><given-names>H</given-names></name><name><surname>Ferrante</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy</article-title>. <source>Inflamm Bowel Dis</source> <year>2011</year>; <volume>17</volume>: <fpage>1846</fpage>–<lpage>1854</lpage>.</citation></ref>
<ref id="bibr7-0961203313490433"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verstappen</surname><given-names>SM</given-names></name><name><surname>King</surname><given-names>Y</given-names></name><name><surname>Watson</surname><given-names>KD</given-names></name><name><surname>Symmons</surname><given-names>DP</given-names></name><name><surname>Hyrich</surname><given-names>KL</given-names></name></person-group>. <article-title>Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register</article-title>. <source>Ann Rheum Dis</source> <year>2011</year>; <volume>70</volume>: <fpage>823</fpage>–<lpage>826</lpage>.</citation></ref>
<ref id="bibr8-0961203313490433"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pons-Estel</surname><given-names>GJ</given-names></name><name><surname>Salerni</surname><given-names>GE</given-names></name><name><surname>Serrano</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature</article-title>. <source>Autoimmun Rev</source> <year>2011</year>; <volume>10</volume>: <fpage>679</fpage>–<lpage>684</lpage>.</citation></ref>
<ref id="bibr9-0961203313490433"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gómez-Puerta</surname><given-names>J</given-names></name><name><surname>Espinosa</surname><given-names>G</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name></person-group>. <article-title>Catastrophic antiphospholipid syndrome: Diagnosis and management in pregnancy</article-title>. <source>Clin Lab Med</source>. <comment>Epub ahead of print 22 April 2013</comment>.</citation></ref>
<ref id="bibr10-0961203313490433"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Haieg</surname><given-names>DO</given-names></name><name><surname>Zanati</surname><given-names>MF</given-names></name><name><surname>El-Foual</surname><given-names>FM</given-names></name></person-group>. <article-title>Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome</article-title>. <source>Int J Gynaecol Obstet</source> <year>2007</year>; <volume>99</volume>: <fpage>236</fpage>–<lpage>241</lpage>.</citation></ref>
</ref-list>
</back>
</article>